<p><b>A</b>. B6, <i>IFNAR1<sup>−/−</sup></i> and <i>Gt</i> mice were injected with 1∶1 ratio WT <i>GFP<sup>+</sup> Ly5.2<sup>+</sup></i> and <i>IFNAR1<sup>−/−</sup> Ly5.1<sup>+</sup></i> OT-I cells 1 day prior to immunization with ActA<sup>−</sup>Lm-OVA (Δ<i>actA</i>) in the presence (open triangles) or absence (open circles) of 50 µg c-di-AMP or administered PBS (closed circles). Splenocytes were isolated 7 days later and stained with anti-mouse CD8 and CD45.1 and analyzed by flow cytometry. Values in representative FACs plots show the median percentage of WT or <i>IFNAR1<sup>−/−</sup></i> OT-I cells ± SEM within the CD8<sup>+</sup> T cell population. <b>B</b>. Quantitative analysis shows the percentage (left panels) within the CD8<sup>+</...
<p>Unfractionated spleen cells of DNA/protein- or DNA-immunized WT mice were stimulated <i>ex vivo</...
<p>(A) Characterization of infiltrating liver lymphocytes isolated from mice immunized with <i>Pyfab...
<p>WT mice (n = 5/group) were treated with anti-IFNAR1 blocking antibody (α-Ifnar1) or control IgG p...
<p>Mice were infected with LCMV CL-13. At 1.5 d p.i., 0.5 mg IFNAR-1 mAb (αIFNAR-1) or its control i...
<p><b>A</b>. B6 or <i>IFNAR1<sup>−/−</sup></i> mice were immunized with 10<sup>3</sup> CFU ActA<sup>...
<p>(A) Mice were infected with the indicated combinations of 1×10<sup>5</sup> CFU ActA-Lm, 1×10<sup>...
<p>C57BL/6 mice were infected with 5*10e4 PbTg iRBC i.v.. Simultaneously, groups of mice received ei...
<p>A. CD4<sup>+</sup>CD62L<sup>hi</sup> T cells were sorted from the spleens and lymph nodes of C57B...
<p>B6 mice were immunized with either 10<sup>3</sup> CFU ActA<sup>−</sup>Lm-OVA (Δ<i>actA</i>) (open...
<p>Spleen, draining lymph nodes and mesenteric lymph node were removed at 5<sup>th</sup> week after ...
<p>C57BL/6 mice (2–3 mice per group) were immunized twice with 1, PBS plus IgG; 2, PBS plus IFN-γ; 3...
<p>Mice were HBSS- (open bars) or poly(I∶C)- (black bars) treated for 1, 2, or 3 days. Splenocytes w...
Lymph node cells isolated from mice after 67 days of infection were cultured for 4 h in a solution w...
<p>Lymphopenic RAG<sup>−/−</sup> mice reconstituted with CellTrace Violet-labeled LN cells from cong...
<p>(A, B) IL-18 production from DCs. (A) DCs isolated from spleen of IFN-γR1<sup>−/−</sup> and wild ...
<p>Unfractionated spleen cells of DNA/protein- or DNA-immunized WT mice were stimulated <i>ex vivo</...
<p>(A) Characterization of infiltrating liver lymphocytes isolated from mice immunized with <i>Pyfab...
<p>WT mice (n = 5/group) were treated with anti-IFNAR1 blocking antibody (α-Ifnar1) or control IgG p...
<p>Mice were infected with LCMV CL-13. At 1.5 d p.i., 0.5 mg IFNAR-1 mAb (αIFNAR-1) or its control i...
<p><b>A</b>. B6 or <i>IFNAR1<sup>−/−</sup></i> mice were immunized with 10<sup>3</sup> CFU ActA<sup>...
<p>(A) Mice were infected with the indicated combinations of 1×10<sup>5</sup> CFU ActA-Lm, 1×10<sup>...
<p>C57BL/6 mice were infected with 5*10e4 PbTg iRBC i.v.. Simultaneously, groups of mice received ei...
<p>A. CD4<sup>+</sup>CD62L<sup>hi</sup> T cells were sorted from the spleens and lymph nodes of C57B...
<p>B6 mice were immunized with either 10<sup>3</sup> CFU ActA<sup>−</sup>Lm-OVA (Δ<i>actA</i>) (open...
<p>Spleen, draining lymph nodes and mesenteric lymph node were removed at 5<sup>th</sup> week after ...
<p>C57BL/6 mice (2–3 mice per group) were immunized twice with 1, PBS plus IgG; 2, PBS plus IFN-γ; 3...
<p>Mice were HBSS- (open bars) or poly(I∶C)- (black bars) treated for 1, 2, or 3 days. Splenocytes w...
Lymph node cells isolated from mice after 67 days of infection were cultured for 4 h in a solution w...
<p>Lymphopenic RAG<sup>−/−</sup> mice reconstituted with CellTrace Violet-labeled LN cells from cong...
<p>(A, B) IL-18 production from DCs. (A) DCs isolated from spleen of IFN-γR1<sup>−/−</sup> and wild ...
<p>Unfractionated spleen cells of DNA/protein- or DNA-immunized WT mice were stimulated <i>ex vivo</...
<p>(A) Characterization of infiltrating liver lymphocytes isolated from mice immunized with <i>Pyfab...
<p>WT mice (n = 5/group) were treated with anti-IFNAR1 blocking antibody (α-Ifnar1) or control IgG p...